Literature DB >> 25388764

Modeling energy intake by adding homeostatic feedback and drug intervention.

Peter Gennemark1, Stephan Hjorth, Johan Gabrielsson.   

Abstract

Energy intake (EI) is a pivotal biomarker used in quantification approaches to metabolic disease processes such as obesity, diabetes, and growth disorders. Eating behavior is however under both short-term and long-term control. This control system manifests itself as tolerance and rebound phenomena in EI, when challenged by drug treatment or diet restriction. The paper describes a model with the capability to capture physiological counter-regulatory feedback actions triggered by energy imbalances. This feedback is general as it handles tolerance to both increases and decreases in EI, and works in both acute and chronic settings. A drug mechanism function inhibits (or stimulates) EI. The deviation of EI relative to a reference level (set-point) serves as input to a non-linear appetite control signal which in turn impacts EI in parallel to the drug intervention. Three examples demonstrate the potential usefulness of the model in both acute and chronic dosing situations. The model shifts the predicted concentration-response relationship rightwardly at lower concentrations, in contrast to models that do not handle functional adaptation. A fourth example further shows that the model may qualitatively explain differences in rate and extent of adaptation in observed EI and its concomitants in both rodents and humans.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25388764     DOI: 10.1007/s10928-014-9399-4

Source DB:  PubMed          Journal:  J Pharmacokinet Pharmacodyn        ISSN: 1567-567X            Impact factor:   2.745


  55 in total

Review 1.  Biomarkers of satiation and satiety.

Authors:  Cees de Graaf; Wendy A M Blom; Paul A M Smeets; Annette Stafleu; Henk F J Hendriks
Journal:  Am J Clin Nutr       Date:  2004-06       Impact factor: 7.045

2.  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus.

Authors:  Willem de Winter; Joost DeJongh; Teun Post; Bart Ploeger; Richard Urquhart; Ian Moules; David Eckland; Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-03-22       Impact factor: 2.745

3.  Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration.

Authors:  M Wakelkamp; G Alván; J Gabrielsson; G Paintaud
Journal:  Clin Pharmacol Ther       Date:  1996-07       Impact factor: 6.875

4.  Feedback modeling of non-esterified fatty acids in obese Zucker rats after nicotinic acid infusions.

Authors:  Christine Ahlström; Tobias Kroon; Lambertus A Peletier; Johan Gabrielsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-10-10       Impact factor: 2.745

5.  Enhanced solubility and bioavailability of sibutramine base by solid dispersion system with aqueous medium.

Authors:  Dong Xun Li; Ki-Young Jang; Wonku Kang; Kyoungjin Bae; Mann Hyung Lee; Yu-Kyoung Oh; Jun-Pil Jee; Young-Joon Park; Dong Hoon Oh; Youn Gee Seo; Young Ran Kim; Jong Oh Kim; Jong Soo Woo; Chul Soon Yong; Han-Gon Choi
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

6.  [The spontaneous periodicity of ad libitum food intake in white rats].

Authors:  J Le Magnen; S Tallon
Journal:  J Physiol (Paris)       Date:  1966 May-Jun

7.  A systems-level analysis of perfect adaptation in yeast osmoregulation.

Authors:  Dale Muzzey; Carlos A Gómez-Uribe; Jerome T Mettetal; Alexander van Oudenaarden
Journal:  Cell       Date:  2009-07-10       Impact factor: 41.582

8.  Modeling the metabolic effects of terbutaline in beta2-adrenergic receptor diplotypes.

Authors:  John J Lima; Nobuko Matsushima; Niranjan Kissoon; Jianwei Wang; James E Sylvester; William J Jusko
Journal:  Clin Pharmacol Ther       Date:  2004-07       Impact factor: 6.875

Review 9.  Target site occupancy: emerging generalizations from clinical and preclinical studies.

Authors:  Sarah Grimwood; Paul R Hartig
Journal:  Pharmacol Ther       Date:  2009-03-21       Impact factor: 12.310

10.  Anti-Obesity Drugs: A Review about Their Effects and Safety.

Authors:  Jun Goo Kang; Cheol-Young Park
Journal:  Diabetes Metab J       Date:  2012-02-17       Impact factor: 5.376

View more
  5 in total

1.  Modeling energy intake and body weight effects of a long-acting amylin analogue.

Authors:  Annika Brings; Jens Markus Borghardt; Jolanta Skarbaliene; Tamara Baader-Pagler; Maria A Deryabina; Wolfgang Rist; Stefan Scheuerer
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-11-23       Impact factor: 2.745

Review 2.  Requirements for multi-level systems pharmacology models to reach end-usage: the case of type 2 diabetes.

Authors:  Elin Nyman; Yvonne J W Rozendaal; Gabriel Helmlinger; Bengt Hamrén; Maria C Kjellsson; Peter Strålfors; Natal A W van Riel; Peter Gennemark; Gunnar Cedersund
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906

3.  Translational Modeling to Guide Study Design and Dose Choice in Obesity Exemplified by AZD1979, a Melanin-concentrating Hormone Receptor 1 Antagonist.

Authors:  P Gennemark; M Trägårdh; D Lindén; K Ploj; A Johansson; A Turnbull; B Carlsson; M Antonsson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2017-05-27

4.  Evaluation of a Mathematical Model of Rat Body Weight Regulation in Application to Caloric Restriction and Drug Treatment Studies.

Authors:  Jangir Selimkhanov; W Clayton Thompson; Terrell A Patterson; John R Hadcock; Dennis O Scott; Tristan S Maurer; Cynthia J Musante
Journal:  PLoS One       Date:  2016-05-26       Impact factor: 3.240

Review 5.  Unlock the Thermogenic Potential of Adipose Tissue: Pharmacological Modulation and Implications for Treatment of Diabetes and Obesity.

Authors:  Xiao-Rong Peng; Peter Gennemark; Gavin O'Mahony; Stefano Bartesaghi
Journal:  Front Endocrinol (Lausanne)       Date:  2015-11-19       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.